STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics (CARA), Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback